Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

Abstract Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME databas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Grinda, Natacha Joyon, Amélie Lusque, Sarah Lefèvre, Laurent Arnould, Frédérique Penault-Llorca, Gaëtan Macgrogan, Isabelle Treilleux, Anne Vincent-Salomon, Juliette Haudebourg, Aurélie Maran-Gonzalez, Emmanuelle Charafe-Jauffret, Coralie Courtinard, Camille Franchet, Véronique Verriele, Etienne Brain, Patrick Tas, Cécile Blanc-Fournier, Agnès Leroux, Delphine Loussouarn, Anca Berghian, Eva Brabencova, Jean Pierre Ghnassia, Jean-Yves Scoazec, Suzette Delaloge, Thomas Filleron, Magali Lacroix-Triki
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f5c605ed13024aff8ffd60be2690e7ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5c605ed13024aff8ffd60be2690e7ab
record_format	dspace
spelling	oai:doaj.org-article:f5c605ed13024aff8ffd60be2690e7ab2021-12-02T14:27:10ZPhenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort10.1038/s41523-021-00252-62374-4677https://doaj.org/article/f5c605ed13024aff8ffd60be2690e7ab2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00252-6https://doaj.org/toc/2374-4677Abstract Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.Thomas GrindaNatacha JoyonAmélie LusqueSarah LefèvreLaurent ArnouldFrédérique Penault-LlorcaGaëtan MacgroganIsabelle TreilleuxAnne Vincent-SalomonJuliette HaudebourgAurélie Maran-GonzalezEmmanuelle Charafe-JauffretCoralie CourtinardCamille FranchetVéronique VerrieleEtienne BrainPatrick TasCécile Blanc-FournierAgnès LerouxDelphine LoussouarnAnca BerghianEva BrabencovaJean Pierre GhnassiaJean-Yves ScoazecSuzette DelalogeThomas FilleronMagali Lacroix-TrikiNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Thomas Grinda Natacha Joyon Amélie Lusque Sarah Lefèvre Laurent Arnould Frédérique Penault-Llorca Gaëtan Macgrogan Isabelle Treilleux Anne Vincent-Salomon Juliette Haudebourg Aurélie Maran-Gonzalez Emmanuelle Charafe-Jauffret Coralie Courtinard Camille Franchet Véronique Verriele Etienne Brain Patrick Tas Cécile Blanc-Fournier Agnès Leroux Delphine Loussouarn Anca Berghian Eva Brabencova Jean Pierre Ghnassia Jean-Yves Scoazec Suzette Delaloge Thomas Filleron Magali Lacroix-Triki Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
description	Abstract Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.
format	article
author	Thomas Grinda Natacha Joyon Amélie Lusque Sarah Lefèvre Laurent Arnould Frédérique Penault-Llorca Gaëtan Macgrogan Isabelle Treilleux Anne Vincent-Salomon Juliette Haudebourg Aurélie Maran-Gonzalez Emmanuelle Charafe-Jauffret Coralie Courtinard Camille Franchet Véronique Verriele Etienne Brain Patrick Tas Cécile Blanc-Fournier Agnès Leroux Delphine Loussouarn Anca Berghian Eva Brabencova Jean Pierre Ghnassia Jean-Yves Scoazec Suzette Delaloge Thomas Filleron Magali Lacroix-Triki
author_facet	Thomas Grinda Natacha Joyon Amélie Lusque Sarah Lefèvre Laurent Arnould Frédérique Penault-Llorca Gaëtan Macgrogan Isabelle Treilleux Anne Vincent-Salomon Juliette Haudebourg Aurélie Maran-Gonzalez Emmanuelle Charafe-Jauffret Coralie Courtinard Camille Franchet Véronique Verriele Etienne Brain Patrick Tas Cécile Blanc-Fournier Agnès Leroux Delphine Loussouarn Anca Berghian Eva Brabencova Jean Pierre Ghnassia Jean-Yves Scoazec Suzette Delaloge Thomas Filleron Magali Lacroix-Triki
author_sort	Thomas Grinda
title	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
title_short	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
title_full	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
title_fullStr	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
title_full_unstemmed	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
title_sort	phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter french esme cohort
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f5c605ed13024aff8ffd60be2690e7ab
work_keys_str_mv	AT thomasgrinda phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT natachajoyon phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT amelielusque phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT sarahlefevre phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT laurentarnould phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT frederiquepenaultllorca phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT gaetanmacgrogan phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT isabelletreilleux phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT annevincentsalomon phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT juliettehaudebourg phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT aureliemarangonzalez phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT emmanuellecharafejauffret phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT coraliecourtinard phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT camillefranchet phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT veroniqueverriele phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT etiennebrain phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT patricktas phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT cecileblancfournier phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT agnesleroux phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT delphineloussouarn phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT ancaberghian phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT evabrabencova phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT jeanpierreghnassia phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT jeanyvesscoazec phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT suzettedelaloge phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT thomasfilleron phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort AT magalilacroixtriki phenotypicdiscordancebetweenprimaryandmetastaticbreastcancerinthelargescalereallifemulticenterfrenchesmecohort
_version_	1718391345868963840

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

Ejemplares similares